Analytical Pitfalls with Tricyclic and Newer Antidepressants in Biological Samples

  • C. Lindsay DeVane
Chapter
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 16 A)

Abstract

With antidepressants and their active metabolites there are analytical complications: low concentrations; surface adsorptivity during extraction; chromatographic co-elution with other drugs and contaminants; and uncertainty about survival during storage and chromatography. Stability experience with the tricyclics does not hold for newer antidepressants. Thus, bupropion (but not its three major metabolites) showed temperature- and pH-dependent log-linear degradation in plasma. The importance of validating extraction techniques for each sample type is exemplified by trazodone, which was extractable from plasma by methyl-t-butyl ether but required isoamyl alcohol/hexane for brain tissue extraction to obviate emulsions and include an active metabolite. For cyclic antidepressants in general, sources of inaccuracy include the preparation of non-methanolic stock solutions, mode of rendering alkaline, standard-curve determination with homogenates of the tissue concerned, and HPLC validation with a converse-polarity system, e.g. NP instead of RP. Other points of practice are also discussed, e.g. sample collection, in the context of inter-laboratory differences in assay performance.

Keywords

Isoamyl Alcohol Cyclic Antidepressant Brain Tissue Extraction Analytical Complication Single Extraction Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gupta, R. & Molnar, G. (1979) Drug Metab. Rev.9, 79–97.CrossRefGoogle Scholar
  2. 2.
    Scoggins, B.A., Maquire, K.P., Norman, T.R. & Burrows, G.D. (1980) Clin. Chem.26, 5–17.Google Scholar
  3. 3.
    Laizure, S.C. & DeVane, C.L. (1986) Ther. Drug Monit.7, 447–450.CrossRefGoogle Scholar
  4. 4.
    Stout, S.A. & DeVane, C.L. (1984) Psychopharmacology84, 39–41.CrossRefGoogle Scholar
  5. 5.
    DeVane, C.L. & Simpkins, J.T. (1985) Drug Metab. Dispos.13, 438–442.Google Scholar
  6. 6.
    Curry, S.H., DeVane, C.L. & Wolfe, M.M. (1985) Eur. J. Clin. Pharmacol.29, 429–433.CrossRefGoogle Scholar
  7. 7.
    Miller, R.L. & DeVane, C.L. (1985) J. Chromatog.374, 388–393.Google Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • C. Lindsay DeVane
    • 1
  1. 1.Division of Clinical Pharmacokinetics, College of PharmacyUniversity of FloridaGainesvilleUSA

Personalised recommendations